Treatment of immuno-resistant disease with low-dose interferon

dc.creator	Cummins, Joseph M., Jr.
dc.date.accessioned	2019-06-17T17:09:48Z
dc.date.available	2019-06-17T17:09:48Z
dc.date.issued	1991-05-28
dc.identifier.uri	https://hdl.handle.net/1969.1/177108
dc.description.abstract	Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of about 0.1 to about 5 IU/lb per day by contacting said interferon with oral/pharyngeal mucosa. Interferon is administered in solution or in a novel solid unitary dosage form adapted to be dissolved in saliva when placed in the mouth.	en
dc.language	eng
dc.publisher	United States. Patent and Trademark Office
dc.rights	Public Domain (No copyright - United States)	en
dc.rights.uri	http://rightsstatements.org/vocab/NoC-US/1.0/
dc.title	Treatment of immuno-resistant disease with low-dose interferon	en
dc.type	Utility patent	en
dc.format.digitalOrigin	reformatted digital	en
dc.description.country	US
dc.contributor.assignee	The Texas A&M University System
dc.identifier.patentapplicationnumber	07/465527
dc.subject.uspcprimary	424/85.4
dc.subject.uspcother	424/85.6
dc.subject.uspcother	424/85.7
dc.date.filed	1990-01-17
dc.publisher.digital	Texas A&M University. Libraries
dc.subject.cpcprimary	A61K 38/212
dc.subject.cpcprimary	A61K 38/21